Skip to content
PsychoGenics logo

PsychoGenics Alternatives & Competitors

12 companies similar to PsychoGenics — Discover Your Next Breakthrough

Companies similar to PsychoGenics

SynapCell logo — alternative to PsychoGenics

SynapCell

Evaluate your most effective drug candidates in vivo using objective & translational measu...

NeuCyte logo — alternative to PsychoGenics

NeuCyte

Decoding CNS Drug Discovery with SynFire® iP

Newron Pharmaceuticals SpA logo — alternative to PsychoGenics

Newron Pharmaceuticals SpA

The Specialist in CNS Drug Development

Farcast Biosciences logo — alternative to PsychoGenics

Farcast Biosciences

24,000 human tumors and counting - building the most precise functional precision tumor mi...

Rival Readout

Competing with PsychoGenics? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
GenFleet Therapeutics logo — alternative to PsychoGenics

GenFleet Therapeutics

Innovation, in Expedition

ALS Therapy Development Institute logo — alternative to PsychoGenics

ALS Therapy Development Institute

We are the world's foremost drug discovery lab focused solely on ALS. Our mission is to di...

Moleculera Biosciences logo — alternative to PsychoGenics

Moleculera Biosciences

A Precision Medicine Company.

Champions Oncology, Inc. logo — alternative to PsychoGenics

Champions Oncology, Inc.

US-based, End-to-End Oncology Pharmacology Solutions CRO

Alcyone Lifesciences logo — alternative to PsychoGenics

Alcyone Lifesciences

Empowering Precision Therapies for Rare Neurological Disorders

Alkermes logo — alternative to PsychoGenics

Alkermes

Alkermes is a global biopharmaceutical company that seeks to develop innovative medicines...

Addex Therapeutics logo — alternative to PsychoGenics

Addex Therapeutics

Allosteric modulators for Human Health

Longboard Pharmaceuticals logo — alternative to PsychoGenics

Longboard Pharmaceuticals

We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases...

About PsychoGenics

PsychoGenics is a preclinical CRO specializing in CNS and orphan disorders, aiming to provide top-tier disease models and comprehensive preclinical capabilities for the discovery of advanced treatments and reduction of attrition rates in clinical development. The company is recognized for its cutting-edge translational...

Business keywords

CNS Disorders, Orphan Disorders, Preclinical CRO, Translational Research, Disease Models, Behavioral Testing, Electrophysiology, Molecular Biology, Microdialysis, Quality Assurance, Biopharmaceutical, Clinical Development, Pharmacology, Neurological Disorders, Research And Development

Frequently Asked Questions

Companies similar to PsychoGenics include SynapCell, NeuCyte, Newron Pharmaceuticals SpA, Farcast Biosciences, GenFleet Therapeutics. They work in Biotechnology and Health Care and share PsychoGenics's focus on neurological disorders, biopharmaceutical and clinical development.
Bounce Watch lists 12 companies that share PsychoGenics's industries and are closest to it in business tags, services, target customers, business model and size.
PsychoGenics is a preclinical CRO specializing in CNS and orphan disorders, aiming to provide top-tier disease models and comprehensive preclinical capabilities for the discovery of advanced treatments and reduction of attrition rates in clinical development. The company is recognized for its cutting-edge translational...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around PsychoGenics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at PsychoGenics on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout